| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00054210 Details | 2020-10-05 Interventional | 3 | - | Albumin-Bound P… Carboplatin Paclitaxel Paclitaxel poli… Carcinoma, Non-… Lung Neoplasms Lung Cancer | - - | |||
| NCT00054197 Details | 2020-10-05 Interventional | 3 | [1 Refs] | - | Gemcitabine Paclitaxel Paclitaxel poli… Vinorelbine Carcinoma, Non-… Lung Neoplasms Lung Cancer | - - | ||
| NCT00054184 Details | 2020-10-05 Interventional | 3 | - | Docetaxel Paclitaxel Paclitaxel poli… Carcinoma, Non-… Lung Neoplasms Lung Cancer | - - | |||
| NCT00020969 Details | 2020-10-05 Interventional | 2 | [1 Refs] | - | Arsenic Trioxid… Leukemia Myelodysplastic… Myelodysplastic… Myeloproliferat… Preleukemia Syndrome Myelodysplastic… | - - | ||
| NCT00017069 Details | 2020-10-05 Interventional | 2 | - | Arsenic Trioxid… Dexamethasone Multiple Myelom… Neoplasms, Plas… Plasmacytoma Multiple Myelom… | - - | |||
| NCT02353780 Details | 2020-10-01 Interventional | 4 | 10 | Abatacept Certolizumab Pe… Etanercept Infliximab Tumor Necrosis … Arthritis Arthritis, Rheu… Rheumatoid Arth… | Low enrollment Due to the small number of patients enrolled in each group, it was not possible to perform statistical analyses of the primary endpoints. These are fairly broad measures that require large numbers to identify patterns in subset changes. | |||
| NCT04085393 Details | 2020-09-30 Interventional | 2 | 0 | Granisetron Nausea Vomiting Chemotherapy-in… | sponsor withdrew study - | |||
| NCT02476955 Details | 2020-09-30 Interventional | 1 | 41 | Albumin-Bound P… Anastrozole Carboplatin Paclitaxel Endometrial Neo… Ovarian Neoplas… Endometrial Can… Ovarian Cancer Solid Tumors | - - | |||
| NCT01942993 Details | 2020-09-30 Interventional | 2 | 3 | Vemurafenib Melanoma | standard of care has changed Too few subjects to assess for correlation. Also no subject underwent tissue tumor biopsy which were not mandatory. | |||
| NCT01080222 Details | 2020-09-30 Interventional | 2 | 152 | Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Hepatitis, Chro… Infections Virus Diseases Chronic Hepatit… | Study discontinued - | |||
| NCT02505087 Details | 2020-09-29 Interventional | 2/3 | 7 | Acetylcysteine N-monoacetylcys… Genetic Disease… Muscular Diseas… Selenoprotein N… | - - | |||
| NCT02283905 Details | 2020-09-29 Interventional | 4 | 2 | Amphotericin B Liposomal ampho… Voriconazole Blastomycosis | Poor enrollment numbers of patients - | |||
| NCT01103024 2009-015509-38 Details | 2020-09-29 Interventional | 3 | 0 | Antibodies, Mon… Uveitis | Core study in non-infectious active uveitis was terminated - | |||
| NCT04116359 Details | 2020-09-28 Interventional | 1/2 | 0 | Cisplatin Etoposide Etoposide phosp… Podophyllotoxin Carcinoma Metastatic NUT … Unresectable NU… | Other - Protocol moved to Disapproved - | |||
| NCT03925428 Details | 2020-09-28 Interventional | 1 | 0 | Entinostat Histone Deacety… Carcinoma Lymphoma Lymphoma, B-Cel… Lymphoma, Non-H… Lymphoma, T-Cel… Neoplasms Pancreatic Neop… Advanced Lympho… Advanced Malign… Ann Arbor Stage… Ann Arbor Stage… Ann Arbor Stage… Ann Arbor Stage… Refractory B-Ce… Refractory Lymp… Refractory Mali… Refractory Panc… Refractory T-Ce… Stage II Pancre… Stage IIA Pancr… Stage IIB Pancr… Stage III Pancr… Stage IV Pancre… Unresectable Pa… | Other - Protocol moved to Disapproved - | |||
| NCT03391856 Details | 2020-09-25 Interventional | 2/3 | 15 | Acetylcysteine N-monoacetylcys… Thrombocytopeni… Stem Cell Trans… | protocol changed - | |||
| NCT01821963 Details | 2020-09-24 Interventional | 3 | 1 | Interferon alph… Interferon-alph… Interferons Peginterferon a… Ribavirin Carcinoma Carcinoma, Hepa… Communicable Di… Infections Infection | Low referral rate due to new therapeutic options. - | |||
| NCT01697293 Details | 2020-09-24 Interventional | 1/2 | 34 | Albumin-Bound P… Cyclophosphamid… Doxorubicin Liposomal doxor… Paclitaxel Breast Neoplasm… Breast Adenocar… Estrogen Recept… HER2/Neu Negati… Recurrent Breas… Stage IIB Breas… Stage IIIA Brea… Stage IIIB Brea… Stage IIIC Brea… Stage IV Breast… | criteria for continuing enrollment in Phase 2 portion was not met - | |||
| NCT01690468 Details | 2020-09-24 Interventional | 1/2 | 15 | Carboplatin Carcinoma, Ovar… Ovarian Neoplas… Ovarian Cancer | Enrollment stopped prior to Phase 1b, change in strategic focus - | |||
| NCT00506948 Details | 2020-09-24 Interventional | 2 | 13 | Antilymphocyte … Mycophenolic Ac… Sirolimus Thymoglobulin Hematologic Neo… Myelodysplastic… Neoplasms Preleukemia Hematological M… Leukemia Lymphoma Myelodysplastic… | Halted due to high incidence of veno-oclusive disease of the liver. A decision to terminate this trial was made due to the high incidence of veno-occlusive disease of the liver in participants receiving this graft-versus-host disease (GVHD) prophylaxis regimen. |